Specialty Pharma Journal Specialty, Precision & Technology
AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it has entered into amendments with The University of Texas MD Anderson Cancer Center (MD Anderson) to extend the …
Tag Archives: md anderson
August, 2018
-
9 August
Jazz and MD Anderson Partner to Evaluate Potential Therapies for Hematologic Malignancies
DUBLIN and HOUSTON, Aug. 6, 2018 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and The University of Texas MD Anderson Cancer Center today announced a five-year collaboration agreement with a goal of evaluating therapies for multiple hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes. The joint effort brings …
July, 2018
-
12 July
Study Shows Biomarker Panel Boosts Lung Cancer Risk Assessment for Smokers
A four-protein biomarker blood test improves lung cancer risk assessment over existing guidelines that rely solely upon smoking history, capturing risk for people who have ever smoked, not only for heavy smokers, an international research team reports in JAMA Oncology. “This simple blood test demonstrates the potential of biomarker-based risk assessment …
June, 2018
-
1 June
Amgen and MD Anderson Announce Two Collaboration Agreements to Accelerate Development of Various Cancer Therapies
THOUSAND OAKS, Calif. and HOUSTON, May 31, 2018 /PRNewswire/ — Amgen (NASDAQ:AMGN) and The University of Texas MD Anderson Cancer Center today announced two multi-year collaboration agreements aimed at accelerating development of a variety of Amgen’s early-stage oncology therapies for patients with leukemia, myelodysplastic syndromes, multiple myeloma, small-cell lung cancer, and other non-lung cancers with small-cell histologies. The agreements combine Amgen therapies …
September, 2017
-
27 September
MD Anderson and Pfizer Collaborate to Evaluate Immuno-Oncology Combinations in Blood Cancers and Solid Tumors
The University of Texas MD Anderson Cancer Center and Pfizer Inc. today announced that they have entered into a clinical collaboration to study novel combinations of three Pfizer investigational immuno-oncology therapies and other Pfizer agents in the treatment of various solid tumors and hematologic malignancies. “This alliance aims to define patients …
-
14 September
Daiichi Sankyo and MD Anderson Collaborate to Accelerate Development of Acute Myeloid Leukemia Therapies
HOUSTON and TOKYO and BASKING RIDGE, N.J., Sept. 14, 2017 /PRNewswire/ — The University of Texas MD Anderson Cancer Center and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced a multi-year collaboration focused on accelerating the development of novel therapies for acute myeloid leukemia (AML). The collaboration represents an …
July, 2017
-
21 July
Concurrent Chemotherapy, Proton Therapy Improves Survival in Patients with Advanced Lung Cancer
HOUSTON – For patients with advanced, inoperable stage 3 lung cancer, concurrent chemotherapy and the specialized radiation treatment, proton therapy, offers improved survival compared to historical data for standard of care, according to a new study from The University of Texas MD Anderson Cancer Center. The research, published in JAMA Oncology, …
March, 2017
-
29 March
Protein Identified as Potential Druggable Target for Pancreatic Cancer
A protein known as arginine methyltransferase 1 (PRMT1) may be a potential therapeutic target for pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, and one of the most deadliest with a less than 10 percent, five-year survival rate. PRMT1 is involved in a number of genetic processes …
February, 2017
-
1 February
MD Anderson and Guardant Health Partner to Make Comprehensive Liquid Biopsy an Oncology Standard of Care
MD Anderson News Release 01/31/2017 The University of Texas MD Anderson Cancer Center and Guardant Health today announced a multi-year partnership designed to accelerate comprehensive liquid biopsy technology into the standard of care in cancer treatment. The commercial, research and development agreement will make MD Anderson among the few hospitals …
November, 2016
-
2 November
MD Anderson-Led Study Develops Prediction Model for Lung Cancer Risk in Never Smokers
Researchers at The University of Texas MD Anderson Cancer Center have developed a new personalized assessment tool that could better predict lung cancer risk in never, light and heavy smokers using a large Taiwanese prospective cohort study. By incorporating risk factors in addition to smoking history, this tool could better …